3L9M
Crystal structure of PKAB3 (pka triple mutant V123A, L173M, Q181K) with compound 18
3L9M の概要
| エントリーDOI | 10.2210/pdb3l9m/pdb |
| 関連するPDBエントリー | 3L9L 3L9N |
| 分子名称 | cAMP-dependent protein kinase catalytic subunit alpha, cAMP-dependent protein kinase inhibitor alpha, (2S)-N~1~-[5-(3-methyl-1H-indazol-5-yl)-1,3,4-thiadiazol-2-yl]-3-(4-methylphenyl)propane-1,2-diamine, ... (4 entities in total) |
| 機能のキーワード | pkb, inhibitor, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
| 由来する生物種 | Homo sapiens (human) 詳細 |
| 細胞内の位置 | Cytoplasm (By similarity): P17612 |
| タンパク質・核酸の鎖数 | 4 |
| 化学式量合計 | 86809.02 |
| 構造登録者 | |
| 主引用文献 | Zeng, Q.,Allen, J.G.,Bourbeau, M.P.,Wang, X.,Yao, G.,Tadesse, S.,Rider, J.T.,Yuan, C.C.,Hong, F.T.,Lee, M.R.,Zhang, S.,Lofgren, J.A.,Freeman, D.J.,Yang, S.,Li, C.,Tominey, E.,Huang, X.,Hoffman, D.,Yamane, H.K.,Fotsch, C.,Dominguez, C.,Hungate, R.,Zhang, X. Azole-based inhibitors of AKT/PKB for the treatment of cancer. Bioorg.Med.Chem.Lett., 20:1559-1564, 2010 Cited by PubMed Abstract: Through a combination of screening and structure-based rational design, we have discovered a series of N(1)-(5-(heterocyclyl)-thiazol-2-yl)-3-(4-trifluoromethylphenyl)-1,2-propanediamines that were developed into potent ATP competitive inhibitors of AKT. Studies of linker strand-binding adenine isosteres identified SAR trends in potency and selectivity that were consistent with binding interactions observed in structures of the inhibitors bound to AKT1 and to the counter-screening target PKA. One compound was shown to have acceptable pharmacokinetic properties and to be a potent inhibitor of AKT signaling and of in vivo xenograft tumor growth in a preclinical model of glioblastoma. PubMed: 20137943DOI: 10.1016/j.bmcl.2010.01.067 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.9 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






